New hyperekplexia mutations provide insight into glycine receptor assembly, trafficking, and activation mechanisms.

Catherine Vincent-Delorme, Elie G Karam, Stephanie Matta, Vivek Jain, Hanna Mandel, Michael Freilinger, Gail E Graham, Emma Hobson, Sue Chatfield, Amanda Krause, Jubran E Rahme, Zaid Afawi, Samuel F Berkovic, Owain W Howell, Jean-François Vanbellinghen, Mark I Rees, Seo-Kyung Chung, Joseph W Lynch, Elizabeth A Jones, Sian-Elin Wood, Jonathan G L Mullins, Angelo Keramidas, Thomas D Cushion, Rhys H Thomas, William O Pickrell, Cheney J G Drew, Amira Masri, Anna Bode, Grace Vassallo, Alfred P Born, Fusun Alehan, Sharon Aharoni, Gerald Bannasch, Marius Bartsch, Bulent Kara

Journal: The Journal of biological chemistry 2014;288(47):33745-33759

PMID: 24108130

Abstract

Hyperekplexia is a syndrome of readily provoked startle responses, alongside episodic and generalized hypertonia, that presents within the first month of life. Inhibitory glycine receptors are pentameric ligand-gated ion channels with a definitive and clinically well stratified linkage to hyperekplexia. Most hyperekplexia cases are caused by mutations in the α1 subunit of the human glycine receptor (hGlyR) gene (GLRA1). Here we analyzed 68 new unrelated hyperekplexia probands for GLRA1 mutations and identified 19 mutations, of which 9 were novel. Electrophysiological analysis demonstrated that the dominant mutations p.Q226E, p.V280M, and p.R414H induced spontaneous channel activity, indicating that this is a recurring mechanism in hGlyR pathophysiology. p.Q226E, at the top of TM1, most likely induced tonic activation via an enhanced electrostatic attraction to p.R271 at the top of TM2, suggesting a structural mechanism for channel activation. Receptors incorporating p.P230S (which is heterozygous with p.R65W) desensitized much faster than wild type receptors and represent a new TM1 site capable of modulating desensitization. The recessive mutations p.R72C, p.R218W, p.L291P, p.D388A, and p.E375X precluded cell surface expression unless co-expressed with α1 wild type subunits. The recessive p.E375X mutation resulted in subunit truncation upstream of the TM4 domain. Surprisingly, on the basis of three independent assays, we were able to infer that p.E375X truncated subunits are incorporated into functional hGlyRs together with unmutated α1 or α1 plus β subunits. These aberrant receptors exhibit significantly reduced glycine sensitivity. To our knowledge, this is the first suggestion that subunits lacking TM4 domains might be incorporated into functional pentameric ligand-gated ion channel receptors.

Address: University of Queensland, Queensland Brain Institute and School of Biomedical Sciences, Queensland 4072, Australia.; Department of Neurology Research and Molecular Neuroscience, Institute of Life Science, College of Medicine, Swansea University Swansea SA2 8PP, United Kingdom.; Department of Neurology Research and Molecular Neuroscience, Institute of Life Science, College of Medicine, Swansea University Swansea SA2 8PP, United Kingdom; Wales Epilepsy Research Network, College of Medicine, Swansea University Swansea SA2 8PP, United Kingdom.; Department of Paediatrics, Division of Child Neurology, Faculty of Medicine, University of Jordan, Amman 11942, Jordan.; Manchester Centre for Genomic Medicine, Central Manchester University Hospitals National Health Service Foundation Trust, Manchester Academic Health Sciences Centre, Manchester M13 9WL, United Kingdom; Manchester Centre for Genomic Medicine, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester Academic Health Sciences Centre, Manchester M13 9WL, United Kingdom.; Royal Manchester Children's Hospital, Central Manchester University Hospitals National Health Service Foundation Trust, Manchester Academic Health Sciences Centre, Manchester M13 9WL, United Kingdom.; Department of Pediatrics, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.; Department of Pediatrics, Division of Child Neurology, Faculty of Medicine, Basşkent University, 06990 Ankara, Turkey.; Institute of Pediatric Neurology, Schneider Children's Medical Center of Israel, Petah Tikva 49202, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69987, Israel.; Neurology Department, Affinity Medical Group, Menasha, Wisconsin 54952.; Department of Neonatology, University Medical Center of the Johannes Gutenberg University Mainz, D-55099 Mainz, Germany.; Kocaeli University Medical Faculty, Department of Pediatrics, Division of Child Neurology, 41380 Kocaeli, Turkey.; Division of Human Genetics, National Health Laboratory Service, and School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, 2000 Johannesburg, South Africa.; Department of Psychiatry and Clinical Psychology, Saint George Hospital University Medical Center, Balamand University, Faculty of Medicine, Beirut 1100 2807, Lebanon.; Royal Children's Hospital Melbourne, Children's Neuroscience Centre, Royal Children's Hospital, Victoria 3052, Australia.; Metabolic Unit, Meyer Children's Hospital, Rambam Medical Center, Technion Faculty of Medicine, Haifa 31096, Israel.; Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, 1090 Vienna, Austria.; Department of Genetics, Children's Hospital of Eastern Ontario, Ottawa, Ontario K1H 8L1, Canada.; Yorkshire Regional Genetic Service, Chapel Allerton Hospital, Leeds, West Yorkshire LS9 7TF, United Kingdom.; Neonatal Unit, Bradford Royal Infirmary, Bradford, West Yorkshire BD9 6RJ, United Kingdom.; Génétique, Pôle Mère, Enfant, Centre Hospitalier d'Arras, 62 000 Arras, France.; Clalit Health Services, Shfaram 20200, Israel.; Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.; Epilepsy Research Centre, Melbourne Brain Centre, Austin Health, Heidelberg 3084, Victoria, Australia.; Institut de Pathologie et de Génétique ASBL/IRSPG, B-6041 Gosselies, Belgium.; University of Queensland, Queensland Brain Institute and School of Biomedical Sciences, Queensland 4072, Australia. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.